Nova BioGenetics Announces Mr. Tim Moses to Step Aside as Nova's CEO, forNew CEO to Take the Head Position within the Company
ATLANTA, Jul 15, 2003 (BUSINESS WIRE) -- F/K/A Healthcare Network Solutions (OTC Bulletin Board: HNWS) announces that Mr. Tim Moses, Founder of Nova is stepping aside as CEO, to open the officer position of CEO, which will be announced in the upcoming future.
About Nova BioGenetics:
Nova BioGenetics, Inc., ("Nova"), is a biopharmaceuticals company headquartered in Atlanta, Georgia. Nova is engaged in the discovery, development, and commercialization of new therapeutic agents that treat life-threatening infectious diseases. Nova BioGenetics' pipeline, for both FDA and EPA regulatory agencies, is based on patented technology and Nova's own initial bench studies, used as a broad base for applications with existing antibiotic compounds. Attaching the patented technology with antibiotic compounds has proven to facilitate potential disruption of bacterial agents thus producing new therapeutic agents to be marketed.
While the company is specifically focused on its biopharmaceutical interests and is presently in a development stage, Nova also operates a division within the company that is responsible for the sale of cutting edge patented and EPA approved antimicrobials and biocides.
Further information on Nova and its line of products can be found by visiting the firm's web site at www.novabiogenetics.com, Ph. 770-650-6508, Fax 770-650-0411, contact Tim Moses, Chairman, Director of Public Securities.
Safe Harbor/Forward-looking Statements:
These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as: developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of Nova; the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. Nova does not undertake to revise or update any forward-looking statement to reflect events or circumstances that may arise after the date hereof.
SOURCE: Nova BioGenetics, Inc.
CONTACT: Nova BioGenetics, Inc., Atlanta
Tim Moses, 770/650-6508
Fax: 770/650-0411
www.novabiogenetics.com
The best weapon against "fear" is "facts"!!
